Lakefront Biotherapeutics, formerly Galapagos, has sold five preclinical CAR-T assets to Belgian startup Armed Cell ...
French-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, ...
U.K. microbiome company Microbiotica has raised £36 million (€43 million), the first close of a Series C round led by the ...
Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule ...
Zealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and ...
AATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for ...
Over the past few years, Belgium’s argenx has become a biotech force to be reckoned with, driven by the success of its ...
Zealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood ...
Swedish biotech Elicera Therapeutics reported complete metabolic responses in eight of 12 patients treated with its ...
Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...
Paris-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results